503A Compounding Pharmacies and Retatrutide: What the Law Permits
Bottom line: No 503A compounding pharmacy may legally compound retatrutide. It has no FDA-approved NDA and is not on any shortage list — the two conditions required under Section 503A of the FD&C Act.
503A Requirements: Does Retatrutide Qualify?
All conditions must be met for 503A compounding to be lawful. Retatrutide fails two of the four.
What Is a 503A Compounding Pharmacy?
Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) governs traditional compounding pharmacies — state-licensed facilities that prepare customized medications for individual patients based on a valid prescription.
503A pharmacies serve an important role in patient care by preparing medications in alternative dosage forms, strengths, or formulations not commercially available. However, this authority is not unlimited.
The Legal Requirements for 503A Compounding
For a 503A pharmacy to lawfully compound a drug, several conditions must be satisfied simultaneously. The drug must either have an FDA-approved New Drug Application (NDA) or appear on the FDA shortage list.
The shortage-list pathway was established to allow compounding of drugs that are in documented short supply — not a general authorization to compound any drug a pharmacy chooses to offer.
Why 503A Compounding of Retatrutide Is Not Permitted
Retatrutide fails both of the key legal requirements for 503A compounding. First, it has no FDA-approved NDA. Eli Lilly's retatrutide is an investigational drug currently in Phase 3 clinical trials.
Second, retatrutide is not on the FDA shortage list. The shortage list applies to commercially available drugs that are in documented short supply. Retatrutide has never been commercially available.
Some vendors attempt to argue that retatrutide is structurally similar to approved GLP-1 drugs and therefore falls under the same compounding permissions. This argument has no legal basis.
FDA Enforcement Against Unlawful Compounding
The FDA has actively pursued enforcement actions against pharmacies and vendors compounding unapproved GLP-1 peptides. Warning letters, product seizures, and injunctions have been issued.
A pharmacy that compounds retatrutide without legal authorization exposes itself to FDA enforcement action, including warning letters, product seizures, consent decrees, and criminal referral.
503A vs. 503B: Both prohibit retatrutide compounding
503B outsourcing facilities operate under a different legal framework but reach the same conclusion: retatrutide cannot be legally compounded. The 503B prohibition is based on the bulk drug substance list, not the shortage list.
Why 503B outsourcing facilities also cannot compound retatrutide →The only legal way to access retatrutide
Authorized clinical trials provide pharmaceutical-grade retatrutide at no cost, under medical supervision, at licensed research sites. No compounding pharmacy can offer this.
How to find a legitimate retatrutide clinical trial →Frequently Asked Questions
Can a 503A pharmacy legally compound retatrutide?
No. According to the FDA, retatrutide cannot be used in compounding under current federal law. For 503A, retatrutide has no applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list. Any 503A pharmacy claiming to compound retatrutide is operating outside federal law.
Why can semaglutide and tirzepatide be compounded but not retatrutide?
Semaglutide and tirzepatide were placed on the FDA shortage list during documented supply shortages, which temporarily permitted compounding under 503A. Retatrutide has never been commercially available and therefore cannot be in shortage. No shortage-list permission exists for it, and it does not meet any of the other 503A eligibility criteria.
Does a state pharmacy license allow a 503A pharmacy to compound retatrutide?
No. State pharmacy licensure governs the practice of pharmacy within the state. It does not override federal law under the FD&C Act. A state-licensed pharmacy that compounds retatrutide is still violating federal law.
What is the risk to a patient who receives compounded retatrutide from a 503A pharmacy?
The patient is receiving an unapproved drug with no verified purity, potency, or sterility. The pharmacy has no legal authority to compound it, and the product has not been manufactured under GMP standards. Health risks include contamination, incorrect dosing, and unknown substituted compounds.
Could retatrutide ever be legally compounded under 503A?
Only if it receives FDA approval AND is subsequently placed on the shortage list, or if it is added to the 503A bulks list. None of these conditions are met as of September 2026. Even after approval, compounding would only be permitted during a documented shortage of the approved commercial product.
What is the only legal way to access retatrutide today?
Through an authorized clinical trial registered on ClinicalTrials.gov. Participants receive pharmaceutical-grade retatrutide at no cost under medical supervision at licensed research sites.